Pramipexole Accord

Country: Kesatuan Eropah

Bahasa: Inggeris

Sumber: EMA (European Medicines Agency)

Beli sekarang

Risalah maklumat Risalah maklumat (PIL)
11-03-2024
Ciri produk Ciri produk (SPC)
11-03-2024
Laporan Penilaian Awam Laporan Penilaian Awam (PAR)
27-09-2016

Bahan aktif:

pramipexole dihydrochloride monohydrate

Boleh didapati daripada:

Accord Healthcare S.L.U.

Kod ATC:

N04BC05

INN (Nama Antarabangsa):

pramipexole

Kumpulan terapeutik:

Anti-Parkinson drugs

Kawasan terapeutik:

Parkinson Disease; Restless Legs Syndrome

Tanda-tanda terapeutik:

Pramipexole Accord is indicated in adults for treatment of the signs and symptoms of idiopathic Parkinson's disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end-of-dose or 'on-off' fluctuations).

Ringkasan produk:

Revision: 10

Status kebenaran:

Authorised

Tarikh kebenaran:

2011-09-29

Risalah maklumat

                                36
B. PACKAGE LEAFLET
Medicinal product no longer authorised
37 PACKAGE LEAFLET: INFORMATION FOR THE USER
PRAMIPEXOLE ACCORD 0.088 MG TABLETS
PRAMIPEXOLE ACCORD 0.18 MG TABLETS
PRAMIPEXOLE ACCORD 0.35 MG TABLETS
PRAMIPEXOLE ACCORD 0.7 MG TABLETS
PRAMIPEXOLE ACCORD 1.1 MG TABLETS
Pramipexole
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
•
Keep this leaflet. You may need to read it again.
•
If you have any further questions, ask your doctor or pharmacist.
•
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
•
If you get any of the side effects, talk to your doctor or pharmacist.
This includes any possible
side effects not listed in this leaflet. See section 4
WHAT IS IN THIS LEAFLET:
1. What Pramipexole Accord is and what it is used for
2. What you need to know before you take Pramipexole Accord
3. How to take Pramipexole Accord
4. Possible side effects
5. How to store Pramipexole Accord
6. Contents of the pack and other information
1.
WHAT PRAMIPEXOLE ACCORD IS AND WHAT IT IS USED FOR
Pramipexole Accord contains the active substance pramipexole and
belongs to a group of medicines
known as dopamine agonists, which stimulate dopamine receptors in the
brain. Stimulation of the
dopamine receptors triggers nerve impulses in the brain that help to
control body movements.
PRAMIPEXOLE ACCORD IS USED TO:
•
treat the symptoms of primary Parkinson’s disease in adults. It can
be used alone or in
combination with levodopa (another medicine for Parkinson’s
disease).
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE PRAMIPEXOLE ACCORD
DO NOT TAKE PRAMIPEXOLE ACCORD:
•
if you are allergic to pramipexole or to any of the other ingredients
of this medicine (listed in
section 6).
WARNINGS AND PRECAUTIONS:
Talk to your doctor before taking Pramipexole Accord. Tell your doctor
if you have (had) or develop
any medical conditions or symptoms, especially any
                                
                                Baca dokumen lengkap
                                
                            

Ciri produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
Medicinal product no longer authorised
2
1.
NAME OF THE MEDICINAL PRODUCT
Pramipexole Accord 0.088 mg tablets
Pramipexole Accord 0.18 mg tablets
Pramipexole Accord 0.35 mg tablets
Pramipexole Accord 0.7 mg tablets
Pramipexole Accord 1.1 mg tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Pramipexole Accord 0.088 mg tablet
Each tablet contains 0.125 mg pramipexole dihydrochloride monohydrate
equivalent to 0.088 mg
pramipexole.
Pramipexole Accord 0.18 mg tablet
Each tablet contains 0.25 mg pramipexole dihydrochloride monohydrate
equivalent to 0.18 mg
pramipexole.
Pramipexole Accord 0.35 mg tablet
Each tablet contains 0.5 mg pramipexole dihydrochloride monohydrate
equivalent to 0.35 mg
pramipexole.
Pramipexole Accord 0.7 mg tablet
Each tablet contains 1.0 mg pramipexole dihydrochloride monohydrate
equivalent to 0.7 mg
pramipexole.
Pramipexole Accord 1.1 mg tablet
Each tablet contains 1.5 mg pramipexole dihydrochloride monohydrate
equivalent to 1.1 mg
pramipexole.
_Please note: _
Pramipexole doses as published in the literature refer to the salt
form.
Therefore, doses will be expressed in terms of both pramipexole base
and pramipexole salt (in
brackets).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Tablet.
Pramipexole Accord 0.088 mg tablet
The tablets are white to off-white, round, flat faced, bevel edged,
with inscription ‘I1’ on one side and
plain on the other side.
Pramipexole Accord 0.18 mg tablet
The tablets are white to off-white, round, flat faced, bevel edged,
with inscription ‘I’ and ‘2’ on either
side of the breakline on one side and breakline on the other side.
The tablet can be divided into two equal doses.
Pramipexole Accord 0.35 mg tablet
The tablets are white to off-white, round, flat faced, bevel edged,
with inscription ‘I’ and ‘3’ on either
side of the breakline on one side and breakline on the other side.
Medicinal product no longer authorised
3
The tablet can be divided into two equal doses.
Pramipexole
                                
                                Baca dokumen lengkap
                                
                            

Dokumen dalam bahasa lain

Risalah maklumat Risalah maklumat Bulgaria 11-03-2024
Ciri produk Ciri produk Bulgaria 11-03-2024
Laporan Penilaian Awam Laporan Penilaian Awam Bulgaria 27-09-2016
Risalah maklumat Risalah maklumat Sepanyol 11-03-2024
Ciri produk Ciri produk Sepanyol 11-03-2024
Laporan Penilaian Awam Laporan Penilaian Awam Sepanyol 27-09-2016
Risalah maklumat Risalah maklumat Czech 11-03-2024
Ciri produk Ciri produk Czech 11-03-2024
Laporan Penilaian Awam Laporan Penilaian Awam Czech 27-09-2016
Risalah maklumat Risalah maklumat Denmark 11-03-2024
Ciri produk Ciri produk Denmark 11-03-2024
Laporan Penilaian Awam Laporan Penilaian Awam Denmark 27-09-2016
Risalah maklumat Risalah maklumat Jerman 11-03-2024
Ciri produk Ciri produk Jerman 11-03-2024
Laporan Penilaian Awam Laporan Penilaian Awam Jerman 27-09-2016
Risalah maklumat Risalah maklumat Estonia 11-03-2024
Ciri produk Ciri produk Estonia 11-03-2024
Laporan Penilaian Awam Laporan Penilaian Awam Estonia 27-09-2016
Risalah maklumat Risalah maklumat Greek 11-03-2024
Ciri produk Ciri produk Greek 11-03-2024
Laporan Penilaian Awam Laporan Penilaian Awam Greek 27-09-2016
Risalah maklumat Risalah maklumat Perancis 11-03-2024
Ciri produk Ciri produk Perancis 11-03-2024
Laporan Penilaian Awam Laporan Penilaian Awam Perancis 27-09-2016
Risalah maklumat Risalah maklumat Itali 11-03-2024
Ciri produk Ciri produk Itali 11-03-2024
Laporan Penilaian Awam Laporan Penilaian Awam Itali 27-09-2016
Risalah maklumat Risalah maklumat Latvia 11-03-2024
Ciri produk Ciri produk Latvia 11-03-2024
Laporan Penilaian Awam Laporan Penilaian Awam Latvia 27-09-2016
Risalah maklumat Risalah maklumat Lithuania 11-03-2024
Ciri produk Ciri produk Lithuania 11-03-2024
Laporan Penilaian Awam Laporan Penilaian Awam Lithuania 27-09-2016
Risalah maklumat Risalah maklumat Hungary 11-03-2024
Ciri produk Ciri produk Hungary 11-03-2024
Laporan Penilaian Awam Laporan Penilaian Awam Hungary 27-09-2016
Risalah maklumat Risalah maklumat Malta 11-03-2024
Ciri produk Ciri produk Malta 11-03-2024
Laporan Penilaian Awam Laporan Penilaian Awam Malta 27-09-2016
Risalah maklumat Risalah maklumat Belanda 11-03-2024
Ciri produk Ciri produk Belanda 11-03-2024
Laporan Penilaian Awam Laporan Penilaian Awam Belanda 27-09-2016
Risalah maklumat Risalah maklumat Poland 11-03-2024
Ciri produk Ciri produk Poland 11-03-2024
Laporan Penilaian Awam Laporan Penilaian Awam Poland 27-09-2016
Risalah maklumat Risalah maklumat Portugis 11-03-2024
Ciri produk Ciri produk Portugis 11-03-2024
Laporan Penilaian Awam Laporan Penilaian Awam Portugis 27-09-2016
Risalah maklumat Risalah maklumat Romania 11-03-2024
Ciri produk Ciri produk Romania 11-03-2024
Laporan Penilaian Awam Laporan Penilaian Awam Romania 27-09-2016
Risalah maklumat Risalah maklumat Slovak 11-03-2024
Ciri produk Ciri produk Slovak 11-03-2024
Laporan Penilaian Awam Laporan Penilaian Awam Slovak 27-09-2016
Risalah maklumat Risalah maklumat Slovenia 11-03-2024
Ciri produk Ciri produk Slovenia 11-03-2024
Laporan Penilaian Awam Laporan Penilaian Awam Slovenia 27-09-2016
Risalah maklumat Risalah maklumat Finland 11-03-2024
Ciri produk Ciri produk Finland 11-03-2024
Laporan Penilaian Awam Laporan Penilaian Awam Finland 27-09-2016
Risalah maklumat Risalah maklumat Sweden 11-03-2024
Ciri produk Ciri produk Sweden 11-03-2024
Laporan Penilaian Awam Laporan Penilaian Awam Sweden 27-09-2016
Risalah maklumat Risalah maklumat Norway 11-03-2024
Ciri produk Ciri produk Norway 11-03-2024
Risalah maklumat Risalah maklumat Iceland 11-03-2024
Ciri produk Ciri produk Iceland 11-03-2024
Risalah maklumat Risalah maklumat Croat 11-03-2024
Ciri produk Ciri produk Croat 11-03-2024
Laporan Penilaian Awam Laporan Penilaian Awam Croat 27-09-2016

Cari amaran yang berkaitan dengan produk ini